四川新首富募资37亿元押宝创新药！18家知名机构争抢认购

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. successfully raised a total of 3.764 billion yuan through a private placement of A-shares, with all funds allocated for innovative drug research and development [2] Fundraising Details - The issuance price was set at 317 yuan per share, representing a 119.16% ratio to the issuance floor price [2] - The fundraising attracted significant interest, with 30 investors submitting bids, and 18 ultimately winning, including major institutions like China Europe Fund Management and E Fund Management [2] - The lock-up period for the shares is set at 6 months [2] Research and Development Focus - The raised funds will primarily target two areas: 1. The ADC (Antibody-Drug Conjugate) drug development platform, advancing clinical trials for six ADC drugs, including BL-B01D1/iza-bren and BL-M07D1, covering over ten indications such as lung and breast cancer [2] 2. The multi-specific antibody platform, accelerating clinical development for GNC-038 and GNC-077, thereby enriching the company's innovative drug pipeline [3] Strategic Goals - The company aims to become a leading entry-level multinational pharmaceutical company in the oncology treatment field within five years, from 2025 to 2029 [3] Leadership and Wealth - Chairman Zhu Yi holds a 74.35% stake in the company, with his net worth estimated at approximately 117.399 billion yuan following a stock price surge to 414.02 yuan per share [3] - Zhu Yi's wealth was previously estimated at 95 billion yuan in the 2025 Hurun Global Rich List [3]